Objectif
Novel concepts to control newly emerging and highly pathogenic Marek's disease virus (vv+ MDV-1) are needed. Different antigen formulations, routes of vaccination, and biological adjuvant will be tested. DNA vaccines encoding MDV-1 antigens expressed in all stages of the virus' life cycle (lytic, latent, tumour stage) will be constructed, with an emphasis on antigens inducing a cytotoxic T cell response. The same proteins will also be expressed by recombinant Sindbis viruses. Modified live vaccines derived from a vv+ MDV-1 strain with a deletion in gB or gM shall be constructed using the bacterial artificial chromosome technique. The routes of vaccination will be
1) in-ovo vaccination and
2) vaccination of 1- day-old chickens via various routes. The cytokine profiles after MDV-1 infection will be analysed by developing new tools and test systems, and rational approaches to immune modulation using biological adjuvant will be developed and tested.
Champ scientifique
- natural sciencesbiological sciencesmicrobiologyvirology
- natural sciencesbiological sciencesgeneticsDNA
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- natural sciencesbiological sciencesgeneticschromosomes
Appel à propositions
Data not availableRégime de financement
CSC - Cost-sharing contractsCoordinateur
17498 INSEL RIEMS
Allemagne